MedPath

Symax International Study

Not Applicable
Completed
Conditions
Prosthesis Durability
Hip Osteoarthritis
Registration Number
NCT03469687
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The uncemented Symax hip stem is developed through optimization of the uncemented Omnifit hip stem. The Symax stem design combines an anatomical anteverted proximal geometry with a straight distal section. The proximal part is coated with a biomimetic hydroxyapatite (HA) coating for improved osseointegration to enhance load transfer and to minimize proximal bone loss. The distal part is treated with an anodization surface treatment in order to prevent distal bone apposition, which is expected to prevent distal loading and reduce proximal stress shielding. Aim of this study is to report mid-term clinical performance and evaluate whether the radiographic features are in line with the design principles of the Symax hip in an international clinical study with 5 years of follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients requiring uncemented primary total hip arthroplasty (osteoarthritis, avascular necrosis and/or post-traumatic arthritis), age between 18-70 years, BMI less or equal to 35.
Exclusion Criteria
  • Patients with bilateral hip complaints, impaired cognitive function and use of medication or illness influencing bone metabolism.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Change of Harris Hip Score (HHS) during follow-upPreoperative HHS and postoperatively change in HHS at 6 months, 1 year, 2 years, 3 years and 5 years

A hip specific functional score

Secondary Outcome Measures
NameTimeMethod
Radiographic evaluationsImmediately postoperative radiograhpic evaluation as baseline and changes in radiography at follow-up 6 months, 1 year, 2 years, 3 years and 5 years we evaluated the radiograhip evaluations again

Radiographic evaluations per Gruen zone and comparison between two assessment teams

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.